MA33360B1 - Composés antiviraux hétérocycliques - Google Patents
Composés antiviraux hétérocycliquesInfo
- Publication number
- MA33360B1 MA33360B1 MA34447A MA34447A MA33360B1 MA 33360 B1 MA33360 B1 MA 33360B1 MA 34447 A MA34447 A MA 34447A MA 34447 A MA34447 A MA 34447A MA 33360 B1 MA33360 B1 MA 33360B1
- Authority
- MA
- Morocco
- Prior art keywords
- antiviral compounds
- heterocyclic antiviral
- heterocyclic
- compounds
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION A POUR OBJET DES COMPOSÉS AYANT LA FORMULE (I), R1, R2, R3, R4, X1, X2, X3 ET X4 ÉTANT TELS QUE DÉFINIS ICI, QUI SONT DES INHIBITEURS DE LA POLYMÉRASE NS5B DU VIRUS DE L'HÉPATITE C. LA PRÉSENTE INVENTION CONCERNE AUSSI DES COMPOSITIONS ET DES PROCÉDÉS POUR LE TRAITEMENT D'UNE INFECTION AU VHC ET L'INHIBITION DE LA RÉPLICATION DU VHC.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18546009P | 2009-06-09 | 2009-06-09 | |
| US26335109P | 2009-11-21 | 2009-11-21 | |
| PCT/EP2010/057958 WO2010142656A1 (fr) | 2009-06-09 | 2010-06-08 | Composés antiviraux hétérocycliques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33360B1 true MA33360B1 (fr) | 2012-06-01 |
Family
ID=42288900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34447A MA33360B1 (fr) | 2009-06-09 | 2010-06-08 | Composés antiviraux hétérocycliques |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8026253B2 (fr) |
| EP (1) | EP2440528B1 (fr) |
| JP (1) | JP5612678B2 (fr) |
| KR (1) | KR101431343B1 (fr) |
| CN (1) | CN102803216B (fr) |
| AR (1) | AR077004A1 (fr) |
| AU (1) | AU2010257592B2 (fr) |
| BR (1) | BRPI1010852A2 (fr) |
| CA (1) | CA2764141C (fr) |
| CO (1) | CO6400218A2 (fr) |
| CR (1) | CR20110605A (fr) |
| EC (1) | ECSP11011513A (fr) |
| ES (1) | ES2525254T3 (fr) |
| IL (1) | IL216412A (fr) |
| MA (1) | MA33360B1 (fr) |
| MX (1) | MX2011013209A (fr) |
| MY (1) | MY157435A (fr) |
| NZ (1) | NZ596646A (fr) |
| PE (2) | PE20151092A1 (fr) |
| RU (1) | RU2540332C2 (fr) |
| SG (1) | SG176762A1 (fr) |
| TW (1) | TWI428332B (fr) |
| WO (1) | WO2010142656A1 (fr) |
| ZA (1) | ZA201108921B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1016266A2 (pt) * | 2009-03-06 | 2019-09-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| BR112013000245A2 (pt) * | 2010-07-07 | 2016-05-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| RU2572835C2 (ru) * | 2010-08-13 | 2016-01-20 | Ф. Хоффманн-Ля Рош Аг | Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с |
| WO2013090929A1 (fr) * | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | Dérivés d'amino-quinoléine inhibiteurs de vhc |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| PE20151203A1 (es) | 2012-10-16 | 2015-08-31 | Janssen Pharmaceutica Nv | MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| HK1213250A1 (zh) | 2012-10-16 | 2016-06-30 | Janssen Pharmaceutica, N.V. | RORγT的雜芳基連接的喹啉基調節劑 |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| CA2927182A1 (fr) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Modulateurs quinolinyl de ror.gamma.t |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| AU2014334619A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| CA2943100C (fr) * | 2014-03-24 | 2017-04-04 | Hao Wu | Derives de quinoleine comme inhibiteurs de smo |
| JP2018525371A (ja) * | 2015-07-30 | 2018-09-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリール置換された二環式ヘテロアリール化合物 |
| JP7252973B2 (ja) | 2018-03-26 | 2023-04-05 | ノバルティス アーゲー | Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ベンズアミド誘導体 |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| EP4031243A1 (fr) * | 2019-09-16 | 2022-07-27 | Novartis AG | Agents de dégradation de colle et leurs procédés d'utilisation |
| WO2021198981A1 (fr) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Composés antiviraux et leurs utilisations |
| CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
| CA3200318A1 (fr) * | 2020-10-30 | 2022-05-05 | 1Cbio, Inc. | Inhibiteurs d'ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) et leurs utilisations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB558009A (en) * | 1942-05-08 | 1943-12-15 | Harold Coates | Quinoline derivatives |
| RU2029472C1 (ru) * | 1989-09-26 | 1995-02-27 | Сумитомо Кемикал Компани Лимитед | Производные урацила, промежуточные соединения, гербицидная композиция и способ борьбы с сорняками |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AU2001261377A1 (en) * | 2000-05-10 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
| AR068108A1 (es) | 2007-08-29 | 2009-11-04 | Schering Corp | Derivados azaindol 2,3-sustituidos y una composicion farmaceutica |
| AU2008295483B2 (en) | 2007-08-29 | 2013-11-21 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| CN101842353A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2,3-取代的吲哚衍生物 |
| EP2639226B1 (fr) | 2007-09-17 | 2016-08-31 | AbbVie Bahamas Ltd. | Pyrimidines anti-infectieuses et leurs utilisations |
| MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
| KR101552474B1 (ko) | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| JP5416708B2 (ja) | 2007-11-16 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法 |
| MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| CN102448952B (zh) | 2009-03-25 | 2014-10-29 | Abbvie公司 | 抗病毒化合物和其用途 |
| CA2755348C (fr) | 2009-03-25 | 2017-12-12 | Abbott Laboratories | Composes antiviraux aryles substitues et leurs utilisations |
-
2010
- 2010-06-07 TW TW099118427A patent/TWI428332B/zh not_active IP Right Cessation
- 2010-06-07 AR ARP100101992A patent/AR077004A1/es unknown
- 2010-06-08 BR BRPI1010852A patent/BRPI1010852A2/pt not_active IP Right Cessation
- 2010-06-08 MX MX2011013209A patent/MX2011013209A/es active IP Right Grant
- 2010-06-08 WO PCT/EP2010/057958 patent/WO2010142656A1/fr not_active Ceased
- 2010-06-08 AU AU2010257592A patent/AU2010257592B2/en not_active Ceased
- 2010-06-08 EP EP10720797.9A patent/EP2440528B1/fr active Active
- 2010-06-08 PE PE2015001204A patent/PE20151092A1/es not_active Application Discontinuation
- 2010-06-08 SG SG2011091212A patent/SG176762A1/en unknown
- 2010-06-08 ES ES10720797.9T patent/ES2525254T3/es active Active
- 2010-06-08 CA CA2764141A patent/CA2764141C/fr not_active Expired - Fee Related
- 2010-06-08 RU RU2011153788/04A patent/RU2540332C2/ru not_active IP Right Cessation
- 2010-06-08 PE PE2011002042A patent/PE20120937A1/es active IP Right Grant
- 2010-06-08 KR KR1020127000604A patent/KR101431343B1/ko not_active Expired - Fee Related
- 2010-06-08 JP JP2012514440A patent/JP5612678B2/ja not_active Expired - Fee Related
- 2010-06-08 MA MA34447A patent/MA33360B1/fr unknown
- 2010-06-08 CN CN201080025186.6A patent/CN102803216B/zh not_active Expired - Fee Related
- 2010-06-08 NZ NZ596646A patent/NZ596646A/en not_active IP Right Cessation
- 2010-06-08 MY MYPI2011005928A patent/MY157435A/en unknown
- 2010-06-09 US US12/797,308 patent/US8026253B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 US US13/212,742 patent/US8487103B2/en not_active Expired - Fee Related
- 2011-11-16 CR CR20110605A patent/CR20110605A/es unknown
- 2011-11-17 IL IL216412A patent/IL216412A/en not_active IP Right Cessation
- 2011-11-24 CO CO11161639A patent/CO6400218A2/es active IP Right Grant
- 2011-12-05 ZA ZA2011/08921A patent/ZA201108921B/en unknown
- 2011-12-09 EC EC2011011513A patent/ECSP11011513A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33360B1 (fr) | Composés antiviraux hétérocycliques | |
| MA30198B1 (fr) | Inhibiteurs de la protease ns3 du vhc | |
| MA30893B1 (fr) | Inhibiteurs de la protease ns3 du vhc | |
| MA31864B1 (fr) | Composés nucléosidiques antiviraux | |
| MA29757B1 (fr) | Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc | |
| MA37942B1 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| EA201170241A1 (ru) | Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3 | |
| MY159958A (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
| MA33209B1 (fr) | Inhibiteurs de la replication du virus de l'hepatite c | |
| MX2012008443A (es) | Nucleosidos antiviricos. | |
| DE602007006796D1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer | |
| EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
| ATE483712T1 (de) | Hcv-ns5b-inhibitoren | |
| MY150667A (en) | Antiviral nucleosides | |
| ATE546460T1 (de) | Hemmer des hepatitis-c-virus | |
| EA200900676A1 (ru) | Ингибиторы вируса гепатита с | |
| MA34896B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| MA32006B1 (fr) | Inhibiteurs de polymerase virale | |
| MA35104B1 (fr) | Inhibiteur du virus de l'hepatite c | |
| ATE533771T1 (de) | Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren | |
| MA37992B1 (fr) | Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c. | |
| EA201170605A1 (ru) | Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства | |
| MX2012006513A (es) | Compuestos heterociclicos antivirales. | |
| MX2011012541A (es) | Compuestos heterociclicos antivirales. |